ZBIO - CIK 0001953926
The table below shows Zenas BioPharma, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$172.33M | -$119.67M | -$30.53M |
| Capital expenditure | $18.00K | $131.00K | $17.00K |
| Investing cash flow | -$251.89M | -$30.55M | -$17.00K |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $215.28M | $412.96M | $20.12M |
Zenas BioPharma, Inc. reported operating cash flow of -$172.33M for fiscal year 2025. That is down 44.0% from -$119.67M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.